Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform ...

Oppenheimer assumed coverage on shares of Alumis (NASDAQ:ALMS – Free Report) in a research note published on Thursday morning, MarketBeat.com reports. The firm issued an outperform rating and a $32.00 ...

Fintel reports that on January 30, 2025, Oppenheimer initiated coverage of Alumis (NasdaqGS:ALMS) with a Outperform ...

Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering ...

Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies ...

Alumis (ALMS) stock gains as Oppenheimer initiates coverage with an Outperform recommendation, citing a valuation disconnect. Read more here.

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of $32 on Thursday, noting that despite the potential in its pipeline ...

Alumis Inc. (NASDAQ:ALMS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the eight brokerages that are presently covering the stock, Marketbeat reports. Six analysts have ...

Jan. 28, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and ...